PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
74.78%
EBIT growth above 1.5x AGEN's 10.36%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
74.78%
Operating income growth above 1.5x AGEN's 10.36%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
64.85%
Net income growth above 1.5x AGEN's 8.55%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
64.71%
EPS growth above 1.5x AGEN's 10.81%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
64.71%
Diluted EPS growth above 1.5x AGEN's 10.81%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-60.52%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-60.52%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
51.61%
Positive long-term OCF/share growth while AGEN is negative. John Neff would see a structural advantage in sustained cash generation.
51.61%
5Y OCF/share CAGR at 75-90% of AGEN's 61.83%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
51.61%
3Y OCF/share CAGR at 50-75% of AGEN's 69.53%. Martin Whitman would suspect weaker recent execution or product competitiveness.
66.06%
Net income/share CAGR above 1.5x AGEN's 13.79% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
66.06%
5Y net income/share CAGR similar to AGEN's 63.32%. Walter Schloss might see both on parallel mid-term trajectories.
66.06%
3Y net income/share CAGR 1.25-1.5x AGEN's 56.37%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.06%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-5.28%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
11.50%
Debt growth of 11.50% while AGEN is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
-73.61%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.